GLP1R and type 2 diabetes mellitus: A comprehensive systematic review of CVOTs [102] clearly showed that GLP-1 RAs reduced the risk of major adverse cardiovascular events (MACEs), all-cause mortality, and worsening kidney function in patients with T2DM, most of whom had ascertained cardiovascular disease, to a significant extent.